Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model | Zendy

Kamrul Islam | Zendy; Fekade B. Sime | Zendy; Steven C. Wallis | Zendy; Michelle J. Bauer | Zendy; Brian M. Forde | Zendy; Patrick N. A. Harris | Zendy; Tahmina Shirin | Zendy; Zakir Hossain Habib | Zendy; Meerjady Sabrina Flora | Zendy; Jason A. Roberts | Zendy

Open Access

Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model

Author(s) -

Kamrul Islam,

Fekade B. Sime,

Steven C. Wallis,

Michelle J. Bauer,

Brian M. Forde,

Patrick N. A. Harris,

Tahmina Shirin,

Zakir Hossain Habib,

Meerjady Sabrina Flora,

Jason A. Roberts

Publication year - 2022

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkac186

Subject(s) - meropenem , piperacillin , piperacillin/tazobactam , tazobactam , microbiology and biotechnology , escherichia coli , antibiotics , medicine , pharmacodynamics , beta lactamase inhibitors , regimen , biology , antibiotic resistance , bacteria , pharmacokinetics , imipenem , pseudomonas aeruginosa , biochemistry , genetics , gene

Urosepsis caused by extended-spectrum β-lactamase (ESBL)-producing Escherichia coli is increasing worldwide. Carbapenems are commonly recommended for the treatment of ESBL infections; however, to minimize the emergence of carbapenem resistance, interest in alternative treatments has heightened.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research